Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Purine analog
Fludarabine
Fludara · Flu
A purine analog that accumulates when kidneys fail and lets tumor lysis do the renal damage.
ModeratePurine nucleoside analog · approved 1991
Chronic lymphocytic leukemiaIndolent non-Hodgkin lymphomaReduced-intensity transplant conditioning
Signature kidney injury
Prerenal / Hemodynamic AKI
Direct nephrotoxicity is uncommon; the chief renal risks are tumor-lysis-syndrome AKI during cytoreduction and increased systemic toxicity when the renally cleared drug accumulates in renal impairment. About 60% of the active metabolite 2-F-ara-A is renally eliminated, so renal function directly drives exposure.
Source: Lichtman et al., Cancer Invest 2002
Mechanism of kidney injury
Fludarabine's active metabolite 2-F-ara-A is substantially renally excreted (~60%), so reduced kidney function raises drug exposure and the risk of severe (including neuro- and myelo-) toxicity, mandating CrCl-based dose adjustment. Rapid lymphocyte kill in high-burden CLL/lymphoma can precipitate tumor lysis syndrome with uric acid/phosphate crystal-mediated tubular obstruction and AKI. Intrinsic tubular nephrotoxicity is not characteristic.
Clinical presentation
Tumor lysis biochemistry (hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia) with rising creatinine, sometimes transient and severe; otherwise enhanced systemic toxicity (cytopenias, immunosuppression, rare neurotoxicity) when clearance is reduced.
Onset
TLS within days of starting therapy; systemic toxicity accrues with impaired clearance.
Reversibility
Reversible
Anticancer mechanism
Fluorinated purine nucleotide analog whose active triphosphate (2-F-ara-ATP) inhibits DNA polymerase, ribonucleotide reductase and DNA primase and induces apoptosis. Used for chronic lymphocytic leukemia, indolent non-Hodgkin lymphoma, and as a (reduced-intensity) transplant-conditioning agent.
Management
Manage TLS with IV fluids, rasburicase and electrolyte correction (dialysis if needed); reduce/hold dose for renal dysfunction. TLS-associated AKI usually recovers with prompt therapy.
Risk factors
- Renal impairment (drug accumulation; dose-adjust, avoid if CrCl <30)
- High tumor burden CLL/lymphoma
- Volume depletion / high baseline uric acid
- Older age
Prevention
- Dose-adjust for creatinine clearance (reduce ~20% for CrCl 30-70; avoid below 30)
- TLS prophylaxis with hydration and allopurinol or rasburicase
- Monitor renal function and electrolytes
Note · Renal relevance is driven by accumulation in renal impairment and by tumor lysis, not by characteristic intrinsic tubular toxicity.
Clinical depth
Renal dose adjustment
Per PK/labeling: reduce dose for CrCl 30-70 mL/min (commonly ~20% reduction) and avoid for CrCl <30 mL/min. Prospective dose-adjustment studies show CrCl-banded dosing yields equivalent exposure and acceptable safety; full dosing in unrecognized impairment risks severe (even fatal neuro-) toxicity.
Dialyzability & ESKD dosing
2-F-ara-A is renally cleared, so ESKD markedly prolongs exposure; data on dialytic removal are limited and fludarabine is generally avoided (rather than dialysis-supported) in severe impairment. In conditioning protocols, PK-guided/reduced dosing is used.
Differential diagnosis
TLS-AKI (post-cytoreduction hyperuricemia/hyperphosphatemia, transient) vs prerenal azotemia vs amplified systemic toxicity from unrecognized renal impairment (cytopenias, neurotoxicity rather than a renal lesion). The key safety question is dosing relative to CrCl, not a specific tubular injury pattern.
Monitoring
- Serum creatinine/CrCl at baseline and across cycles (drives dosing)
- TLS panel (uric acid, K, phosphate, calcium) early in high-burden disease
- CBC and neurologic status (accumulation-related toxicity)
Key trials & series
- Lichtman Cancer Invest 2002 - prospective renal-impairment PK/dose-adjustment study (~60% renal elimination of 2-F-ara-A)
- FCR first-line CLL experience (Bouvet Haematologica 2012) - dose reductions including for renal impairment
- Marotta Haematologica 2000 - fludarabine CLL therapy complicated by TLS with transient severe renal impairment
Clinical pearls
- Always dose fludarabine to CrCl - it accumulates in renal impairment and full dosing below CrCl 30 risks severe, sometimes fatal, neurotoxicity.
- The renal injury you see is usually TLS, not tubular toxicity - prophylax in high-burden CLL/lymphoma.
- Roughly 60% of the active metabolite is renally cleared, so the kidney is the dominant determinant of exposure.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of purine analogs.
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Mucositis and diarrhea
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Transaminitis (methotrexate)
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Methotrexate / gemcitabine pneumonitis
Evidence
7 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkThe pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.Lichtman SM et al. · Cancer Invest 2002 · PMID 12449721Key renal PK study; ~60% renal elimination, CrCl-based dose adjustment gives equivalent exposure/safety.PMIDDevelopment of fludarabine formulations in the treatment of chronic lymphocytic leukemia.Janssens A et al. · Drug Des Devel Ther 2009 · PMID 20054443States dose adjustment is mandatory in renal impairment to avoid increased toxicity.PMIDPharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.Ivaturi V et al. · Biol Blood Marrow Transplant 2017 · PMID 28684371PK/PD modeling showing renal function drives f-ara-a exposure; supports renal dose individualization.PMIDImpact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.Bouvet E et al. · Haematologica 2012 · PMID 23065520Real-world FCR cohort; dose reductions (including for renal impairment) and outcomes.PMIDLow-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.Marotta G et al. · Haematologica 2000 · PMID 11114133Fludarabine-based CLL therapy complicated by tumor lysis with transient severe renal impairment.PMIDCisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.Seymour JF et al. · Cancer 2002 · PMID 11857288Fludarabine-containing regimen with a fatal tumor lysis syndrome event.PMIDAnticancer drug-induced kidney disorders.Kintzel PE · Drug Saf 2001 · PMID 11219485Onconephrology context for nucleoside-analog renal handling and tumor-lysis injury.
Related agents
Other agents sharing the same signature kidney injury.